GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (CHIX:PHARMa) » Definitions » Change In Payables And Accrued Expense

Pharming Group (CHIX:PHARMA) Change In Payables And Accrued Expense : €3.2 Mil (TTM As of Mar. 2025)


View and export this data going back to 2008. Start your Free Trial

What is Pharming Group Change In Payables And Accrued Expense?

Pharming Group's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was €-2.6 Mil. It means Pharming Group's Accounts Payable & Accrued Expense declined by €2.6 Mil from Dec. 2024 to Mar. 2025 .

Pharming Group's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was €-2.6 Mil. It means Pharming Group's Accounts Payable & Accrued Expense declined by €2.6 Mil from Dec. 2023 to Dec. 2024 .


Pharming Group Change In Payables And Accrued Expense Historical Data

The historical data trend for Pharming Group's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Change In Payables And Accrued Expense Chart

Pharming Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Payables And Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.77 -4.60 11.32 14.88 -2.64

Pharming Group Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.66 6.65 5.91 -6.76 -2.64

Pharming Group Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharming Group Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Pharming Group's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharming Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (CHIX:PHARMa) » Definitions » Change In Payables And Accrued Expense
Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Pharming Group Headlines

No Headlines